SCHEMBL575795

SCHEMBL575795

C1CCC(SSC2CCCC2)C1

nearest known ligand 0.36

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.36
THRB P10828 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11419865 0.96 ALDH1A1 (0.33) ALDH1A1
SCHEMBL7618850 0.96 ALDH1A1 (0.33) ALDH1A1
SCHEMBL22406167 0.96 ALDH1A1 (0.33) ALDH1A1
SCHEMBL299921 0.96 ALDH1A1 (0.33) ALDH1A1
SCHEMBL10887320 0.96 ALDH1A1 (0.33) ALDH1A1
SCHEMBL2198710 0.91
SCHEMBL31462481 0.84 ALDH1A1 (0.31) ALDH1A1
SCHEMBL31157781 0.84 ALDH1A1 (0.31) ALDH1A1
SCHEMBL31462477 0.84 ALDH1A1 (0.31) ALDH1A1
SCHEMBL23510269 0.81 TXN (0.31) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552997-B2 Targeted disulfide reduction in petroleum matrices CHEVRON U.S.A. INC. (US) 2026-02-17 US claimed
US-7202235-B2 Tetracycline compounds for treatment of cryptosporidium parvum related disorders TRUSTEES OF TUFTS COLLEGE (US) 2007-04-10 US claimed
US-20050215532-A1 Tetracycline compounds for treatment of cryptosporidium parvum related disorders TRUSTEES OF TUFTS COLLEGE (US) 2005-09-29 US claimed
EP-1263442-A1 TETRACYCLINE COMPOUNDS FOR TREATMENT OF i CRYPTOSPORIDIUM PARVUM /i RELATED DISORDERS TRUSTEES OF TUFTS COLLEGE (US) 2002-12-11 EP claimed
US-20020115644-A1 Tetracycline compounds for treatment of Cryptosporidium parvum related disorders PARATEK PHARMACEUTICALS, INC. 2002-08-22 US claimed
WO-2001052858-A1 TETRACYCLINE COMPOUNDS FOR TREATMENT OF CRYPTOSPORIDIUM PARVUM RELATED DISORDERS TRUSTEES OF TUFTS COLLEGE (US) 2001-07-26 WO claimed
CN-121574079-A Method for synthesizing dithioalkyl ketone compound by using diisopropylamine 苏州大学 2026-02-27 CN disclosed
US-12552997-B2 Targeted disulfide reduction in petroleum matrices CHEVRON U.S.A. INC. (US) 2026-02-17 US disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
US-20240297344-A1 NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-05 US disclosed
CN-118271233-A Nilaparil manufacturing method 特沙诺有限公司 2024-07-02 CN disclosed
WO-2024097698-A1 TARGETED DISULFIDE REDUCTION IN PETROLEUM MATRICES CHEVRON U.S.A. INC. (US) 2024-05-10 WO disclosed
US-20240141238-A1 Targeted Disulfide Reduction in Petroleum Matrices CHEVRON U.S.A. INC. 2024-05-02 US disclosed
WO-1984004092-A1 (HYDROCARBYLTHIO)PHENOLS AND THEIR PREPARATION ETHYL CORP (US) 1984-10-25 WO disclosed
EP-0122203-A1 (Hydrocarbylthio)phenols and their preparation ETHYL CORPORATION (US) 1984-10-17 EP disclosed
US-4324920-A REACTION OF A PHENOL WITH A HYDROCARBYL DISULFIDE IN THE PRESENCE OF AN ALUMINUM PHENOXIDE ETHYL CORPORATION (US) 1982-04-13 US disclosed
US-4219393-A ELECTROLYTIC OXIDATION OUCHI SHINKO KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1980-08-26 US disclosed
US-4133830-A RECYCLING BY-PRODUCTS TO SUCCESSIVE RUNS TO IMPROVE YIELD STAUFFER CHEMICAL COMPANY (US) 1979-01-09 US disclosed
US-4000190-A FROM DIALKYL OR DIARYL DISULFIDES, PHOSPHORUS, AND PHOSPHORUS TRIHALIDE STAUFFER CHEMICAL COMPANY (US) 1976-12-28 US disclosed
US-3971820-A TETRAMIZATION OF HALOGEN CYANIDE, BASIC CATALYST NIPPON SODA COMPANY LIMITED (JA) 1976-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115644-A1 Tetracycline compounds for treatment of Cryptosporidium parvum related disorders TUBA1C, TUBB6, TUBB1 ALDH1A1 4471/4885THRB 331/4885MEN1 3438/4885
US-12552997-B2 Targeted disulfide reduction in petroleum matrices DDHD2, ATP2A2, ORAI1 ALDH1A1 584/4885THRB 4036/4885MEN1 3714/4885
US-20050215532-A1 Tetracycline compounds for treatment of cryptosporidium parvum related disorders TUBA1C, TUBB6, TUBB1 ALDH1A1 4471/4885THRB 331/4885MEN1 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.